Choosing the right animal model for sarcoma research
Top Cited Papers
Open Access
- 10 January 2026
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Abstract
Sarcomas comprise over 100 mesenchymal malignancies characterised by extreme genomic heterogeneity, ranging from fusion-driven paediatric tumours to highly unstable adult leiomyosarcomas. This genetic complexity shapes tumour behaviour, influences growth and metastasis, and determines how patients respond to therapy. Accurate animal models must reflect not only the molecular characteristics of these tumours, but also their microenvironment and dynamic interaction with the host immune system. The diversity of this group of cancers presents different challenges for animal model selection, particularly as sarcoma-specific resources are very limited. Therefore, we have reviewed in detail several types of models, including: syngeneic (e.g., MCA205 and KRIMS series), chemically induced (e.g., MCA, DMBA), cell-derived xenografts (CDX; e.g., KCS8 and KCS9 osteosarcoma lines), patient-derived xenograft (PDX; e.g., pleomorphic leiomyosarcoma and GIST models), including humanised PDX (huPDX; e.g. HuNOG-EXL), and zebrafish (e.g. tp53M214K PNST and EWS-FLI1 transgenics) - to illustrate their sarcoma-specific use cases and discuss their advantages and limitations. Genetically engineered models and their development are not a subject of this review, as they represent a very broad subject independently and are discussed elsewhere. Graphical abstractKeywords
Funding Information
- Narodowym Centrum Nauki (2019/35/O/NZ2/03761 (AMC))
This publication has 162 references indexed in Scilit:
- PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD‐1 blockadeClinical and Translational Medicine, 2024
- Establishment of an orthotopic perirenal space xenograft mouse model of retroperitoneal sarcomaCancer Communications, 2021
- Ewing Sarcoma PDX Models2020
- Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue SarcomasJAMA, 2020
- Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor PalbociclibJAMA Oncology, 2016
- An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testingVirchows Archiv, 2014
- Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP‐1 and TIMP‐2 and tumor thrombospondin‐1International Journal of Cancer, 2014
- Morphological and carbogen‐based functional MRI of a chemically induced liver tumor model in miceMagnetic Resonance in Medicine, 2003
- Prognostic factors for patients with localized soft‐tissue sarcoma treated with conservation surgery and radiation therapyCancer, 2003
- Effect of solvents on methylcholanthrene-induced carcinogenesis in miceInternational Journal of Cancer, 1981